Eli Lilly (LLY) vs. Meta Platforms (META)
This page compares Eli Lilly (LLY) with Meta Platforms (META) using performance and risk, profitability, financial strength, growth, dividends, and valuation metrics.
Company Profile
Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Meta Platforms (META) belongs to Communication Services (Media & Entertainment) — their GICS classifications point to very different parts of the market.
| Symbol | LLY | META |
|---|---|---|
| Name | Eli Lilly and Company | Meta Platforms Inc Class A |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Communication Services |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Media & Entertainment |
| GICS Industry | Pharmaceuticals | Interactive Media & Services |
| GICS Sub-Industry | Pharmaceuticals | Interactive Media & Services |
| Market Capitalization | 985.37 billion USD | 1,605.58 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 1, 1972 | May 18, 2012 |
| Security Type | Common Stock | Common Stock |
Valuation
Price-to-Earnings Ratio (TTM)
Both Eli Lilly (LLY) at 39.21 and Meta Platforms (META) at 22.99 post Price-to-Earnings Ratio (TTM) near the typical industry midpoint — neither company stands out strongly from peers on trailing earnings multiple.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.21
- Max
- 77.51
- Q3
- 42.45
- Median
- 25.47
- Q1
- 14.64
- Min
- 1.58
META
Media & Entertainment industry group
22.99
- Max
- 68.48
- Q3
- 37.74
- Median
- 23.45
- Q1
- 12.57
- Min
- 1.75
Price-to-Sales Ratio (TTM)
Eli Lilly (LLY) at 13.64 is priced about in line with its industry on Price-to-Sales Ratio (TTM), while Meta Platforms (META) at 7.47 sits in the pricier quartile — META costs more per dollar of sales.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.64
- Max
- 60.01
- Q3
- 26.95
- Median
- 6.83
- Q1
- 3.43
- Min
- 0.01
META
Media & Entertainment industry group
7.47
- Max
- 7.72
- Q3
- 3.58
- Median
- 1.49
- Q1
- 0.58
- Min
- 0.00
Price-to-Book Ratio (MRQ)
Both look rich against book: Meta Platforms (META) at 6.59 sits in the upper Price-to-Book Ratio (MRQ) quartile, and Eli Lilly (LLY) at 31.65 prices even higher, above its industry range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.65
- Max
- 12.80
- Q3
- 6.35
- Median
- 3.45
- Q1
- 1.69
- Min
- -4.09
META
Media & Entertainment industry group
6.59
- Max
- 12.86
- Q3
- 5.96
- Median
- 1.98
- Q1
- 0.78
- Min
- -3.46
Valuation at a Glance
| Symbol | LLY | META |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 39.21 | 22.99 |
| Price-to-Sales Ratio (TTM) | 13.64 | 7.47 |
| Price-to-Book Ratio (MRQ) | 31.65 | 6.59 |
| Free Cash Flow Yield | 0.93% | 1.59% |
Profitability
Return on Equity (TTM)
Eli Lilly (LLY) leads with Return on Equity (TTM) of 107.46%, above its industry benchmark range, while Meta Platforms (META) at 32.93% also ranks strongly in the top quartile.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.46%
- Max
- 94.73%
- Q3
- 2.50%
- Median
- -32.62%
- Q1
- -61.80%
- Min
- -157.07%
META
Media & Entertainment industry group
32.93%
- Max
- 38.89%
- Q3
- 15.20%
- Median
- 6.34%
- Q1
- -4.34%
- Min
- -29.59%
Net Profit Margin (TTM)
Both Eli Lilly (LLY) at 34.99% and Meta Platforms (META) at 32.84% keep an unusually large share of revenue as bottom-line profit — each Net Profit Margin (TTM) clears its industry’s benchmark range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.99%
- Max
- 11.21%
- Q3
- 3.34%
- Median
- 0.00%
- Q1
- -2.04%
- Min
- -9.05%
META
Media & Entertainment industry group
32.84%
- Max
- 30.77%
- Q3
- 10.56%
- Median
- 3.37%
- Q1
- -3.41%
- Min
- -24.17%
Operating Profit Margin (TTM)
Both Eli Lilly (LLY) at 49.39% and Meta Platforms (META) at 40.62% squeeze more operating profit from each sales dollar than most peers, ranking in the top Operating Profit Margin (TTM) quartile of their industries.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
49.39%
- Max
- 100.30%
- Q3
- 3.47%
- Median
- 0.00%
- Q1
- -138.44%
- Min
- -337.81%
META
Media & Entertainment industry group
40.62%
- Max
- 41.37%
- Q3
- 16.41%
- Median
- 7.22%
- Q1
- -3.67%
- Min
- -27.39%
Profitability at a Glance
| Symbol | LLY | META |
|---|---|---|
| Return on Equity (TTM) | 107.46% | 32.93% |
| Return on Assets (TTM) | 20.74% | 16.40% |
| Net Profit Margin (TTM) | 34.99% | 32.84% |
| Operating Profit Margin (TTM) | 49.39% | 40.62% |
| Gross Profit Margin (TTM) | 82.83% | 81.94% |
Growth
Revenue Growth
Revenue Growth at a Glance
| Symbol | LLY | META |
|---|---|---|
| 1-Year Revenue Growth | 44.70% | 22.17% |
| 3-Year Revenue CAGR | 31.69% | 19.89% |
EPS Growth
EPS Growth at a Glance
| Symbol | LLY | META |
|---|---|---|
| 1-Year EPS Growth | 95.99% | -1.55% |
| 3-Year EPS CAGR | 51.71% | 39.84% |
Financial Strength
Current Ratio (MRQ)
Meta Platforms (META) at 2.35 carries Current Ratio (MRQ) above its industry mid-range, while Eli Lilly (LLY) at 1.50 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.50
- Max
- 24.81
- Q3
- 11.93
- Median
- 5.83
- Q1
- 2.73
- Min
- 0.23
META
Media & Entertainment industry group
2.35
- Max
- 4.37
- Q3
- 2.33
- Median
- 1.37
- Q1
- 0.89
- Min
- 0.31
Debt-to-Equity Ratio (MRQ)
Meta Platforms (META) at 0.36 carries Debt-to-Equity Ratio (MRQ) around its industry mid-range, while Eli Lilly (LLY) at 1.39 sits in the higher-leverage quartile.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 1.60
- Q3
- 0.67
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
META
Media & Entertainment industry group
0.36
- Max
- 2.46
- Q3
- 1.35
- Median
- 0.53
- Q1
- 0.17
- Min
- 0.00
Financial Strength at a Glance
| Symbol | LLY | META |
|---|---|---|
| Current Ratio (MRQ) | 1.50 | 2.35 |
| Debt-to-Equity Ratio (MRQ) | 1.39 | 0.36 |
| Net Debt / EBITDA | 1.05 | 0.05 |
Dividends
Dividend Yield (TTM)
Eli Lilly (LLY) at 0.63% reports Dividend Yield (TTM) around its industry mid-range, while Meta Platforms (META) at 0.33% drops into the bottom quartile.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63%
- Max
- 6.57%
- Q3
- 3.18%
- Median
- 1.97%
- Q1
- 0.62%
- Min
- 0.27%
META
Media & Entertainment industry group
0.33%
- Max
- 9.67%
- Q3
- 4.66%
- Median
- 2.41%
- Q1
- 1.22%
- Min
- 0.23%
Dividend Payout Ratio (TTM)
Meta Platforms (META) at 7.64% maintains Dividend Payout Ratio (TTM) around its industry median — a balanced dividend policy. Eli Lilly (LLY) at 22.13% sits outside the typical mid-range, leaning toward more retention or more distribution than the industry median.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.13%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
META
Media & Entertainment industry group
7.64%
- Max
- 49.56%
- Q3
- 21.65%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividends at a Glance
| Symbol | LLY | META |
|---|---|---|
| Dividend Yield (TTM) | 0.63% | 0.33% |
| Dividend Payout Ratio (TTM) | 22.13% | 7.64% |
Performance & Risk
Performance & Risk at a Glance
| Symbol | LLY | META |
|---|---|---|
| 1-Year Return | 54.01% | -1.64% |
| 1-Year Volatility | 37.89% | 34.86% |
| Beta | 0.52 | 1.23 |
| 3-Month Avg. Volume | 3.11M | 15.75M |